Published in Arch Med Sci on April 22, 2013
Influence of cancer cachexia on drug liver metabolism and renal elimination in rats. J Cachexia Sarcopenia Muscle (2015) 0.98
Changes in cardiac output with age. Circulation (1955) 2.94
Comparative influence of load versus inotropic states on indexes of ventricular contractility: experimental and theoretical analysis based on pressure-volume relationships. Circulation (1987) 1.90
Nexfin noninvasive continuous blood pressure validated against Riva-Rocci/Korotkoff. Am J Hypertens (2009) 1.64
Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Curr Cardiol Rev (2011) 1.50
Cardiac cachexia: a systematic overview. Pharmacol Ther (2008) 1.49
An evaluation of cardiac output by five arterial pulse contour techniques during cardiac surgery. Anaesthesia (2007) 1.38
A comparative study of the palliative care needs of heart failure and cancer patients. Eur J Heart Fail (2009) 1.37
Blood volume, cardiac output, and distribution of systemic blood flow in extreme obesity. Cardiovasc Res Cent Bull (1963) 1.25
Comparison of noninvasive cardiac output measurements using the Nexfin monitoring device and the esophageal Doppler. J Clin Anesth (2012) 1.23
Borderline hypertension and obesity: two prehypertensive states with elevated cardiac output. Circulation (1982) 1.16
A comparison of the Nexfin® and transcardiopulmonary thermodilution to estimate cardiac output during coronary artery surgery. Anaesthesia (2012) 1.15
Diabetes mellitus, cachexia and obesity in heart failure: rationale and design of the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF). J Cachexia Sarcopenia Muscle (2010) 1.10
Cardiovascular effects of obesity and hypertension. Lancet (1982) 1.07
Cancer fatigue syndrome reflects clinically non-overt heart failure: an approach towards onco-cardiology. Nat Clin Pract Oncol (2008) 0.99
Comparison of noninvasive continuous arterial waveform analysis (Nexfin) with transthoracic Doppler echocardiography for monitoring of cardiac output. J Clin Anesth (2012) 0.98
Invasive hemodynamic assessment in heart failure. Heart Fail Clin (2009) 0.95
Noninvasive cardiac output and blood pressure monitoring cannot replace an invasive monitoring system in critically ill patients. BMC Anesthesiol (2009) 0.94
Neurohormonal activation and inflammation in chronic cardiopulmonary disease: a brief systematic review. Wien Klin Wochenschr (2009) 0.91
Impact of non invasive and beat-to-beat arterial pressure monitoring on intraoperative hemodynamic management. J Clin Monit Comput (2012) 0.88
Normal cardiac output in relation to age and body size. Tohoku J Exp Med (1979) 0.86
Continuous non-invasive blood pressure monitoring, a validation study of Nexfin in a pregnant population. Hypertens Pregnancy (2009) 0.85
Time to dP/dtmax, a preload-independent index of contractility: open-chest dog study. Basic Res Cardiol (1996) 0.82
Noninvasive blood pressure measurement by the Nexfin monitor during reduced arterial pulsatility: a feasibility study. ASAIO J (2010) 0.81
Anthracycline-induced cardiotoxicity: cardiac monitoring by continuous wave-Doppler ultrasound cardiac output monitoring and correlation to echocardiography. Onkologie (2012) 0.81
Cachexia in heart disease: highlights from the ESC 2010. J Cachexia Sarcopenia Muscle (2011) 0.80
Cardio-renal cachexia syndromes (CRCS): pathophysiological foundations of a vicious pathological circle. J Cachexia Sarcopenia Muscle (2011) 0.80
Leukocyte redistribution: effects of beta blockers in patients with chronic heart failure. PLoS One (2009) 0.79
A comparison of bolus versus continuous cardiac output in an experimental model of heart failure. Crit Care Med (2000) 0.78
2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2013) 12.73
Definition and classification of cancer cachexia: an international consensus. Lancet Oncol (2011) 7.78
Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med (2012) 6.60
The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation (2006) 6.58
Frailty consensus: a call to action. J Am Med Dir Assoc (2013) 6.54
Cachexia: a new definition. Clin Nutr (2008) 5.49
Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med (2009) 4.98
Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation (2003) 3.89
Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J (2005) 3.89
Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial. Lancet (2008) 3.71
Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur Heart J (2009) 3.52
Digoxin reduces 30-day all-cause hospital admission in older patients with chronic systolic heart failure. Am J Med (2013) 3.46
State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail (2008) 3.35
State of the science: promoting self-care in persons with heart failure: a scientific statement from the American Heart Association. Circulation (2009) 3.05
The effect of micronutrient supplementation on quality-of-life and left ventricular function in elderly patients with chronic heart failure. Eur Heart J (2005) 2.92
Impact of remote telemedical management on mortality and hospitalizations in ambulatory patients with chronic heart failure: the telemedical interventional monitoring in heart failure study. Circulation (2011) 2.87
Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation (2002) 2.71
Associations of body fat and its changes over time with quality of life and prospective mortality in hemodialysis patients. Am J Clin Nutr (2006) 2.67
Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. Eur J Heart Fail (2010) 2.64
Muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF). Eur Heart J (2012) 2.60
The obesity paradox and mortality associated with surrogates of body size and muscle mass in patients receiving hemodialysis. Mayo Clin Proc (2010) 2.55
A single dose of erythropoietin in ST-elevation myocardial infarction. Eur Heart J (2010) 2.52
Ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcopenia and Muscle. J Cachexia Sarcopenia Muscle (2010) 2.49
Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J Am Coll Cardiol (2007) 2.46
Sarcopenia with limited mobility: an international consensus. J Am Med Dir Assoc (2011) 2.34
Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure. J Am Coll Cardiol (2005) 2.28
Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol (2010) 2.25
Prediction of mode of death in heart failure: the Seattle Heart Failure Model. Circulation (2007) 2.22
Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J Am Coll Cardiol (2009) 2.20
Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J (2011) 2.14
The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol (2003) 2.12
Ursodeoxycholic acid in patients with chronic heart failure: a double-blind, randomized, placebo-controlled, crossover trial. J Am Coll Cardiol (2012) 2.11
Cachexia as a major underestimated and unmet medical need: facts and numbers. J Cachexia Sarcopenia Muscle (2010) 2.04
Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival. Circulation (2006) 2.00
Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial. Eur Heart J (2013) 1.99
Suppression of endothelial progenitor cells in human coronary artery disease by the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine. J Am Coll Cardiol (2005) 1.99
Autonomic dysfunction predicts mortality in patients with multiple organ dysfunction syndrome of different age groups. Crit Care Med (2005) 1.99
Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol (2007) 1.92
An overview of sarcopenia: facts and numbers on prevalence and clinical impact. J Cachexia Sarcopenia Muscle (2010) 1.89
Inverse relation of body weight and weight change with mortality and morbidity in patients with type 2 diabetes and cardiovascular co-morbidity: an analysis of the PROactive study population. Int J Cardiol (2011) 1.89
Palliative care in heart failure: a position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail (2009) 1.86
Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. Eur Heart J (2008) 1.84
Anemia and inflammation in COPD. Chest (2005) 1.83
Risk factor paradox in wasting diseases. Curr Opin Clin Nutr Metab Care (2007) 1.82
Secretory sphingomyelinase is upregulated in chronic heart failure: a second messenger system of immune activation relates to body composition, muscular functional capacity, and peripheral blood flow. Eur Heart J (2007) 1.75
Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study. Circ Heart Fail (2009) 1.73
Dose-escalated conformal radiotherapy of glioblastomas -- results of a retrospective comparison applying radiation doses of 60 and 70 Gy. Onkologie (2005) 1.72
Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. Circulation (2002) 1.70
Prevalence, incidence and clinical impact of cachexia: facts and numbers-update 2014. J Cachexia Sarcopenia Muscle (2014) 1.68
Autonomic dysfunction predicts both 1- and 2-month mortality in middle-aged patients with multiple organ dysfunction syndrome. Crit Care Med (2008) 1.66
Exercise training in heart failure: from theory to practice. A consensus document of the Heart Failure Association and the European Association for Cardiovascular Prevention and Rehabilitation. Eur J Heart Fail (2011) 1.61
Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail (2009) 1.61
Age-dependent impairment of endothelial progenitor cells is corrected by growth-hormone-mediated increase of insulin-like growth-factor-1. Circ Res (2007) 1.61
Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches. Nat Rev Cardiol (2011) 1.59
Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Circulation (2004) 1.59
Anorexia in chronic obstructive pulmonary disease--association to cachexia and hormonal derangement. Int J Cardiol (2006) 1.58
Neurohormonal activation and the chronic heart failure syndrome in adults with congenital heart disease. Circulation (2002) 1.58
Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll Cardiol (2008) 1.57
Beyond the cardiorenal anaemia syndrome: recognizing the role of iron deficiency. Eur J Heart Fail (2012) 1.56
Absence of obesity paradox in patients with chronic heart failure and diabetes mellitus: a propensity-matched study. Eur J Heart Fail (2010) 1.55
Improvement of cardiac function by intracoronary freshly isolated bone marrow cells transplantation in patients with acute myocardial infarction. Circ J (2011) 1.55
Body mass and survival in patients with chronic heart failure without cachexia: the importance of obesity. J Card Fail (2003) 1.54
Bisoprolol vs. carvedilol in elderly patients with heart failure: rationale and design of the CIBIS-ELD trial. Clin Res Cardiol (2008) 1.53
Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail (2013) 1.53
Nutritional recommendations for the management of sarcopenia. J Am Med Dir Assoc (2010) 1.51
Prevalence, incidence, and clinical impact of sarcopenia: facts, numbers, and epidemiology-update 2014. J Cachexia Sarcopenia Muscle (2014) 1.50
Cardiac cachexia: a systematic overview. Pharmacol Ther (2008) 1.49
Altered intestinal function in patients with chronic heart failure. J Am Coll Cardiol (2007) 1.48
C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study. Eur Heart J (2009) 1.48
The small intestine: a critical linkage in pathophysiology of cardiac cachexia. Int J Cardiol (2010) 1.46